Introduction
============

Extracorporeal membrane oxygenation (ECMO) is used to treat patients in critical condition with life-threatening respiratory failure or cardiogenic shock. In particular, veno-arterial (V-A) ECMO is increasingly being utilized to treat patients whose cardiopulmonary failure is refractory to conventional care,[@b1-cia-12-1347],[@b2-cia-12-1347] and improves the outcome of cardiac resuscitation in patients with cardiogenic shock or arrest due to ischemic heart disease.[@b3-cia-12-1347],[@b4-cia-12-1347]

While the acute survival benefit of V-A ECMO has been demonstrated,[@b5-cia-12-1347] there have been few studies on elderly patients.[@b6-cia-12-1347]--[@b9-cia-12-1347] Moreover, indications for the use of ECMO have yet to be established, and the use of V-A ECMO in elderly patients remains controversial. According to Extracorporeal Life Support Organization guidelines, advanced age is a contraindication for cardiac failure, whereas there are no restrictions on age for respiratory failure.[@b10-cia-12-1347] However, the importance of ECMO for cardiopulmonary resuscitation is expected to rise due to increased life expectancies.

Previous studies have reported that V-A ECMO is also effective at resuscitating elderly patients, yielding a survival rate similar to that of younger patients.[@b7-cia-12-1347],[@b11-cia-12-1347] However, they did not present the differences of predictive factors for survival between older and younger patients. The purpose of this study was to investigate the impact of age on V-A ECMO survival of patients with cardiac failure. Furthermore, we analyzed the predictive factors for survival by dividing patients into two groups according to age.

Materials and methods
=====================

Study population
----------------

This was a retrospective, single-center, observational study which was conducted between May 2009 and May 2016. Patients aged 18 years or older who underwent ECMO were enrolled. We excluded subjects with veno-venous ECMO (n=19). In total, 95 V-A ECMO patients were included in the study. Data obtained from medical records, clinical case histories, and laboratory investigations were reviewed retrospectively. Follow-up data were collected from outpatient clinic records or via the telephone. The composite outcome was all-cause mortality at 90 days post-ECMO initiation. This study was approved by the Institutional Review Board of the Catholic University of Korea, St Vincent's Hospital (IRB approval number: VC16RISI0131). The study was exempted from requirements for written informed consent because we reviewed the medical records retrospectively. All data records were de-identified and analyzed anonymously.

ECMO and management
-------------------

The ECMO team consisted of interventional cardiologists, cardiovascular surgeons, and perfusionists. Use of ECMO is usually considered under conditions of cardiac failure that is refractory to conventional care; typical causes are acute myocardial infarction (AMI), myocarditis, pulmonary thromboembolism (PTE), decompensated chronic heart failure, and post-cardiotomy shock. A Capiox emergency bypass system (Terumo, Tokyo, Japan) was used in all cases. Anti-coagulation was accomplished through a bolus (100 units/kg) injection of unfractionated heparin followed by continuous intravenous infusion to maintain an activated clotting time of between 180 and 220 sec. Successful weaning was defined as separation from ECMO without reinsertion of ECMO or mortality within 24 hrs. All patients underwent blood transfusion to maintain a hematocrit level of 30%--35%, and platelets were infused when the platelet count was \<100,000/µL. Urine output, arterial blood gas analysis, electrolyte, and serum glucose levels were also monitored.

Statistical analysis
--------------------

To investigate the baseline characteristic differences in age, continuous variables were expressed as the median and inter-quartile ranges or the mean ± SD, and compared using Mann--Whitney test or Student's *t*-test. Categorical variables were expressed as numbers and percentages, and compared using the chi-square test or Fisher's exact test. The survival of groups according to age was determined using the Kaplan--Meier method and compared using a log-rank test. HRs of a composite outcome were calculated with Cox regression models. We performed pre-specified analyses stratified according to the following variables: age (≥65 years vs \<65 years), sex, myocarditis or PTE, AMI, diabetes mellitus (DM), hypertension. Logistic regression analysis was performed to determine independent predictors associated with survival. Variables with significant associations using univariate analysis (*P*\<0.05) were entered into the multivariate analysis. ORs and 95% CIs were also calculated. A *P*-value \<0.05 was considered statistically significant. Analyses were performed using Statistical Analysis Software (SAS, version 9.2, SAS Institute Inc., Cary, NC, USA).

Results
=======

Baseline patient characteristics
--------------------------------

Baseline patient characteristics are shown in [Table 1](#t1-cia-12-1347){ref-type="table"}. Patients were classified into "age ≥65" (n=48, 50.5%) and "age \<65" (n=47, 49.5%) groups. There was no difference in ECMO weaning between those two groups (age \<65, 24/47, 51.1% and age ≥65, 16/48, 33.3%, *P*=0.354). However, there was a significant difference in the number of older patients (age ≥65 years) who died during their hospital stay (age \<65, 25/47, 53.2% and age ≥65, 40/48, 83.3%, *P*=0.002). And more patients in the age ≥65 group had DM and hypertension compared with the age \<65 group.

Survival outcomes
-----------------

[Figure 1](#f1-cia-12-1347){ref-type="fig"} shows the higher survival rate at 90 days in the age \<65 group in V-A ECMO patients (log-rank, *P*=0.022). Univariate Cox regression analyses showed that age ≥65 group was significantly associated with increased mortality (HR: 1.715; 95% CI =1.038--2.831) ([Table 2](#t2-cia-12-1347){ref-type="table"}). However, after adjusting for comorbidities, the associations between age ≥65 group and increased mortality were attenuated (HR: 1.485; 95% CI =0.844--2.614) ([Table 3](#t3-cia-12-1347){ref-type="table"}).

Predictors of V-A ECMO mortality
--------------------------------

Independent predictors of V-A ECMO mortality were determined by univariate and multivariate logistic regression analyses. Age (especially ≥65), history of hypertension, myocarditis or PTE for ECMO indication, low Glasgow Coma Scale (GCS) score, high Acute Physiology and Chronic Health Evaluation II (APACHE II) score, low pre-ECMO serum bicarbonate, and high pre-ECMO serum creatinine were significant univariate predictors of mortality ([Table 4](#t4-cia-12-1347){ref-type="table"}). Among these factors, multivariate analysis revealed that age ≥65 (OR 5.750; 95% CI \[1.508--21.920\]; *P*=0.010), low pre-ECMO serum bicarbonate (OR 0.884; 95% CI \[0.788--0.991\]; *P*=0.035), and high pre-ECMO serum creatinine (OR 4.546; 95% CI \[1.021--20.239\]; *P*=0.047) were independent predictors of mortality of V-A ECMO ([Table 4](#t4-cia-12-1347){ref-type="table"}). To estimate the differences of predictors according to the group divided by age ≥65, multivariate logistic regression analysis was performed within each group. In the age \<65 group, bicarbonate, potassium, creatinine level, and APACHE II score were significant univariate predictors of mortality ([Table 5](#t5-cia-12-1347){ref-type="table"}). However, high pre-ECMO serum potassium level (OR 3.552; 95% CI \[1.023--12.331\]; *P*=0.046) was the only independent predictor of mortality of V-A ECMO in the age \<65 group, while low GCS score (OR 0.698; 95% CI \[0.478--1.019\]; *P*=0.063) showed only a considerable trend toward significance in the age ≥65 group ([Table 6](#t6-cia-12-1347){ref-type="table"}).

Discussion
==========

In our study, we investigated the impact of age on V-A ECMO survival of patients with cardiac failure. We also analyzed the predictive factors of survival by dividing patients into two groups according to age. The age ≥65 group showed a higher mortality rate; however, after adjusting for comorbidities, age was no longer an independent risk factor of mortality. Additionally, age ≥65, low pre-ECMO serum bicarbonate, and high pre-ECMO serum creatinine were identified as independent predictors of mortality of V-A ECMO. Our study showed that the predictive factors of mortality differ between those two groups.

V-A ECMO has been successfully used to treat cardio-genic shock and cardiac arrest refractory to usual resuscitation, and the survival benefit of V-A ECMO has been demonstrated.[@b5-cia-12-1347] However, there are few studies on elderly patients.[@b6-cia-12-1347]--[@b9-cia-12-1347] Moreover, indications for the use of ECMO are still unclear, and the use of V-A ECMO for elderly patients remains controversial. However, the importance of ECMO for cardiopulmonary resuscitation is expected to rise as society ages.

Old age is a well-known predictive factor for poor survival of ECMO.[@b12-cia-12-1347] In addition, some factors such as the APACHE score, acute kidney injury or renal replacement therapy, the existence of peripheral artery disease, and asystole or pulseless electrical activity before ECMO introduction, are associated with a worse prognosis.[@b13-cia-12-1347]--[@b18-cia-12-1347] In contrast, acute myocarditis, high GCS score, and successful reperfusion therapy for acute coronary syndrome are associated with better prognosis.[@b12-cia-12-1347],[@b17-cia-12-1347],[@b18-cia-12-1347]

However, there are currently two studies that have reported that V-A ECMO in elderly patients is also effective, yielding a survival rate similar to that of younger patients.[@b7-cia-12-1347],[@b11-cia-12-1347] Saito et al[@b7-cia-12-1347] conducted a single-center trial to evaluate the impact of V-A ECMO on the survival of patients with cardiogenic shock. They concluded that ECMO is also effective at resuscitating elderly patients, yielding a hospital survival rate similar to that of younger patients. However, in that study, the number of patients in the elderly group was relatively low, because the cut-off level for the elderly group was set at 75 years. Narotsky et al reported that old age was not independently associated with short-term or long-term survival among V-A ECMO patients. However, in that study, the laboratory findings, electrocardiogram, and underlying diseases before ECMO insertion were not recorded. In addition, specific multivariate models stratified by age group were not included.[@b11-cia-12-1347] In our study, there was no significant difference in ECMO weaning between groups. However, more patients in the age ≥65 group died during their hospital stay. After adjusting for comorbidities, older age was not an independent risk factor of mortality at 90 days among V-A ECMO patients. These results were probably due to comorbidities with advanced age.

In the present study, age ≥65, low pre-ECMO serum bicarbonate, and high pre-ECMO serum creatinine were identified as independent predictors of mortality of VA-ECMO. Moreover, our study shows that the predictive factors for mortality differ between groups. In the younger group, bicarbonate, potassium, creatinine level, and APACHE II score were significant univariate predictors of mortality. However, in the younger group, high pre-ECMO serum potassium level was the only independent predictor of V-A ECMO mortality, while low GCS score showed only a considerable trend toward significance in the elderly group. The clinical indices of metabolic acidosis such as lower serum bicarbonate, high serum anion gap or acidic urine pH have been associated with well-known risk factors for all-cause and cardiovascular mortality in a healthy population.[@b19-cia-12-1347],[@b20-cia-12-1347] These results may explain why low pre-ECMO serum bicarbonate was an independent predictor of mortality of VA-ECMO. In addition, in previous studies, it was shown that the anaerobic function of central nervous system white matter declines with age and favorable outcome after stroke and brain injuries declines with age.[@b21-cia-12-1347]--[@b23-cia-12-1347] These results may explain why low GCS score was the important factor in mortality of older patients compared to younger patients. Meanwhile, serum potassium levels strongly influence the excitability of cardiomyocytes and muscle cells. Hyperkalemia in cardiogenic shock is related to acute kidney injury, breakdown of muscle fibers, and destruction of red blood cells. Moreover, hyperkalemia is associated with cardiovascular events and mortality.[@b24-cia-12-1347] Usually, younger patients have more muscle mass than older patients. These results may explain why high potassium level was the important factor in mortality of younger patients.

The strength of the present study is that the laboratory findings and mental status before ECMO introduction were measured and investigated among a relatively large sample of elderly patients. However, the present study has several limitations. First, it is a retrospective observational study. However, ECMO support is a difficult problem with regard to randomization because the necessity for V-A ECMO often arises suddenly. The generalizability of results is increased by its observational status, representing real-world practice. Second, we did not calculate other scores such as the Simplified Acute Physiology Score II or Sepsis-related Organ Failure Assessment, which are known predictor factors of survival of ECMO. Third, the number of patients alive at 90 days is too small. The associations between age and increased mortality were attenuated in multivariate Cox regression analysis. This result was probably due to the small sample size and comorbidities with advanced age. We need large sample sizes to address this important issue. Finally, our study included heterogeneous patients such as both post-operative and non-operative, as well as both in-hospital cardiac arrest and out-of-hospital cardiac arrest. Despite these limitations, the present results emphasize the importance of understanding the impact of age in V-A ECMO survival in resuscitating patients and the differences among predictive factors of V-A ECMO mortality by dividing patients into two groups according to age.

In conclusion, older age was not an independent risk factor of mortality at 90 days among V-A ECMO patients after adjustment for comorbidities. In addition, our study provides understanding of the differences in predictive factors for ECMO survival according to age. Pre-ECMO laboratory findings and mental status can assist clinicians in the prediction of a patient's prognosis.
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###### 

Baseline characteristics

  --------------------------------------------------------------------------------------------
  Variables                          Age \<65\              Age ≥65\               *P*-value
                                     (n=47)                 (n=48)                 
  ---------------------------------- ---------------------- ---------------------- -----------
  Male, n (%)                        31 (66.0)              28 (58.3)              0.444

  Mean age (years), mean ± SD        49.2±10.9              74.8±5.8               \<0.001

  ECMO indication                                                                  0.008

   Myocarditis, n (%)                8 (17.0)               0 (0.0)                0.003

   PTE, n (%)                        7 (14.9)               5 (10.4)               0.511

   AMI, n (%)                        18 (38.3)              31 (64.6)              0.010

   Decompensated HF, n (%)           0 (0.0)                4 (8.3)                0.117

   Post-cardiotomy, n (%)            3 (6.4)                2 (4.2)                0.677

   Idiopathic VT/V.fib, n (%)        4 (8.5)                2 (4.2)                0.435

   Other, n (%)                      7 (14.9)               4 (8.3)                0.318

  Current smoker, n (%)              27 (57.4)              20 (41.7)              0.124

  CAD, n (%)                         6 (12.8)               14 (29.2)              0.050

  CVA, n (%)                         1 (2.1)                6 (12.5)               0.053

  DM, n (%)                          7 (14.9)               17 (35.4)              0.021

  Hypertension, n (%)                14 (29.8)              32 (66.7)              \<0.001

  CKD, n (%)                         0 (0.0)                3 (6.3)                0.082

  Cardiac arrest, n (%)              29 (61.7)              27 (56.3)              0.589

  IHCA, n (%)                        17 (63.2)              17 (35.4)              

  OHCA, n (%)                        12 (25.5)              10 (20.8)              

  CA to ROSC time (min) (IQR)        40.0 (20.0--62.0)      38.0 (18.0--55.0)      0.676

  ECG before ECMO                                                                  0.147

   Asystole, n (%)                   7 (14.9)               10 (20.8)              

   PEA, n (%)                        9 (19.2)               10 (20.8)              

   VT/V.fib, n (%)                   9 (19.2)               2 (4.2)                

   Other, n (%)                      22 (46.8)              26 (54.2)              

  GCS score before ECMO, mean ± SD   8.0±5.1                7.7±5.0                0.826

  APACHE II score, mean ± SD         18.9±7.2               21.5±7.8               0.093

  Pre-ECMO laboratory finding                                                      

   pH, mean ± SD                     7.2±0.2                7.3±0.2                0.227

   HCO3 (mmol/L), mean ± SD          14.4±5.0               15.5±5.8               0.365

   Potassium (mEq/L), mean ± SD      4.2±0.8                4.3±1.0                0.835

   Creatinine (mg/dL), mean ± SD     1.3±0.7                1.5±1.2                0.499

   Platelet (×10^9^/L) (IQR)         181.0 (111.0--253.0)   163.5 (123.5--230.0)   0.832

   Total bilirubin (mg/dL) (IQR)     0.6 (0.4--1.2)         0.8 (0.5--1.1)         0.793

   CK-MB (ng/mL) (IQR)               10.2 (3.1--37.7)       9.9 (3.0--48.1)        0.845

  ECMO weaning, n (%)                24 (51.1)              16 (33.3)              0.354

  ECMO duration (days), mean ± SD    7.1±6.3                8.1±7.5                0.514

  Death in hospital, n (%)           25 (53.2)              40 (83.3)              0.002

  Complications                                                                    

   AKI, n (%)                        21 (44.7)              20 (41.7)              0.767

   CRRT, n (%)                       17 (36.2)              14 (29.2)              0.467

   Cannula site bleeding, n (%)      11 (23.4)              8 (16.7)               0.412
  --------------------------------------------------------------------------------------------

**Abbreviations:** ECMO, extracorporeal membrane oxygenation; PTE, pulmonary thromboembolism; AMI, acute myocardial infarction; HF, heart failure; VT, ventricular tachycardia; V.fib, ventricular fibrillation; CAD, coronary artery disease; CVA, cerebrovascular accident; DM, diabetes mellitus; CKD, chronic kidney disease; IHCA, in-hospital cardiac arrest; OHCA, out of hospital cardiac arrest; CA, cardiac arrest; ROSC, return of spontaneous circulation; IQR, inter-quartile range; ECG, electrocardiography; PEA, pulseless electrical activity; GCS, Glasgow Coma Scale; APACHE II, Acute Physiology and Chronic Health Evaluation II; CK-MB, creatine kinase MB; AKI, acute kidney injury; CRRT, continuous renal replacement therapy.

###### 

Univariate Cox regression model

  Age   HR      95% CI         *P*-value
  ----- ------- -------------- -----------
  ≥65   1.715   1.038--2.831   0.035

**Abbreviations:** HR, hazard ratio; CI, confidence interval.

###### 

Multivariate Cox regression model

  Variables            HR      95% CI         *P*-value
  -------------------- ------- -------------- -----------
  Age ≥65              1.485   0.844--2.614   0.170
  Sex                  1.029   0.593--1.786   0.919
  Myocarditis or PTE   0.548   0.230--1.305   0.174
  AMI                  1.074   0.611--1.886   0.805
  DM                   0.855   0.480--1.522   0.594
  Hypertension         1.163   0.660--2.050   0.602

**Abbreviations:** PTE, pulmonary thromboembolism; AMI, acute myocardial infarction; DM, diabetes mellitus; HR, hazard ratio.

###### 

Logistic regression analysis for independent predictors of V-A ECMO mortality in total

  Variables            Univariate   Multivariate                                    
  -------------------- ------------ --------------- ------- ------- --------------- -------
  Age ≥65              4.400        1.700--11.389   0.002   5.750   1.508--21.920   0.010
  Myocarditis or PTE   0.278        0.100--0.772    0.014   0.299   0.072--1.246    0.097
  Hypertension         2.483        1.006--6.125    0.048   1.831   0.503--6.667    0.359
  HCO3                 0.909        0.835--0.990    0.029   0.884   0.788--0.991    0.035
  Potassium            1.713        0.971--3.023    0.063                           
  Creatinine           3.523        1.192--10.415   0.023   4.546   1.021--20.239   0.047
  GCS score            0.888        0.812--0.971    0.009   0.358   0.059--2.164    0.263
  Asystole or PEA      2.647        0.996--7.033    0.051                           
  APACHE II            1.123        1.049--1.202    0.001   1.020   0.896--1.162    0.763

**Abbreviations:** V-A ECMO, venous-arterial extracorporeal membrane oxygenation; PTE, pulmonary thromboembolism; GCS, Glasgow Coma Scale; PEA, pulseless electrical activity; APACHE II, Acute Physiology and Chronic Health Evaluation II.

###### 

Logistic regression analysis for independent predictors of V-A ECMO mortality in age \<65 group

  Variables            Univariate   Multivariate                                    
  -------------------- ------------ --------------- ------- ------- --------------- -------
  Myocarditis or PTE   0.300        0.083--1.090    0.067                           
  HCO3                 0.853        0.730--0.996    0.045   0.861   0.707--1.050    0.139
  Potassium            4.013        1.359--11.847   0.012   3.552   1.023--12.331   0.046
  Creatinine           5.517        1.148--26.513   0.033   2.660   0.519--13.634   0.241
  GCS                  0.925        0.824--1.039    0.188                           
  Asystole or PEA      2.671        0.749--9.529    0.130                           
  APACHE II            1.118        1.018--1.227    0.019   1.110   0.987--1.249    0.083

**Abbreviations:** V-A ECMO, venous-arterial extracorporeal membrane oxygenation; PTE, pulmonary thromboembolism; GCS, Glasgow Coma Scale; PEA, pulseless electrical activity; APACHE II, Acute Physiology and Chronic Health Evaluation II.

###### 

Logistic regression analysis for independent predictors of V-A ECMO mortality in age ≥65 group

  Variables         Univariate   Multivariate                                   
  ----------------- ------------ --------------- ------- ------- -------------- -------
  Cardiac arrest    2.500        0.523--11.956   0.251                          
  HCO3              0.893        0.782--1.021    0.097                          
  Creatinine        2.645        0.451--15.520   0.281                          
  GCS               0.787        0.652--0.950    0.013   0.698   0.478--1.019   0.063
  Asystole or PEA   2.455        0.441--13.670   0.305                          
  APACHE II         1.127        1.001--1.268    0.049   0.916   0.728--1.152   0.453

**Abbreviations:** V-A ECMO, venous-arterial extracorporeal membrane oxygenation; GCS, Glasgow Coma Scale; PEA, pulseless electrical activity; APACHE II, Acute Physiology and Chronic Health Evaluation II.
